Market Research Logo

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018

Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018

Summary

Diabetes refers to a group of metabolic diseases that result from defects in insulin secretion, insulin action or both of these. Type I diabetes is an autoimmune disease in which the pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. There are 263 products in development for this indication.

Type 2 diabetes, however, results from a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. Type 2 diabetes is more closely related to lifestyle choices such as diet and exercise habits than type I diabetes, with the majority of patients being overweight or obese.There are 574 products in development for this indication.

Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. There are 10 products in development for this indication.

Hyperglycemia is a condition that occurs when blood glucose levels get too high. Several factors can contribute to hyperglycemia, including food and physical activity choices, illness, non-diabetes medications, or not taking enough glucose-lowering medication. There are seven products in development for this indication.

Molecular targets acted on by products in development for diabetes and associated metabolic conditions include the insulin receptor, glucagon-like peptide 1 (GLP-1) receptor, glucagon receptor and glucokinase. Companies operating in this pipeline space include Novo Nordisk, Eli Lilly and Zealand Pharma.

This report “Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for diabetes and associated metabolic conditions. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for type I diabetes, type II diabetes, hyperinsulinemia and hyperglycemia, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes and Associated Metabolic Conditions Report Coverage
2.2 Type1 diabetes (Juvenile Diabetes) - Overview
2.3 Hyperinsulinemia - Overview
2.4 Hyperglycemia - Overview
3 Therapeutics Development
3.1 Type1 diabetes (Juvenile Diabetes)
3.2 Type2 diabetes
3.3 Hyperinsulinemia
3.4 Hyperglycemia
4 Therapeutics Assessment
4.1 Type1 diabetes (Juvenile Diabetes)
4.2 Type2 diabetes
4.3 Hyperinsulinemia
4.4 Hyperglycemia
5 Companies Involved in Therapeutics Development
5.1 Type1 diabetes (Juvenile Diabetes)
5.2 Type2 diabetes
5.3 Hyperinsulinemia
5.4 Hyperglycemia
6 Dormant Projects
6.1 Type1 diabetes (Juvenile Diabetes)
6.2 Type2 diabetes
6.3 Hyperinsulinemia
6.4 Hyperglycemia
7 Discontinued Products
7.1 Type1 diabetes (Juvenile Diabetes)
7.2 Type2 diabetes
7.3 Hyperglycemia
8 Product Development Milestones
8.1 Type1 diabetes (Juvenile Diabetes)
8.2 Type2 diabetes
8.3 Hyperinsulinemia
9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Number of Products under Development for Type1 diabetes (Juvenile Diabetes)
Table 2: Number of Products under Development by Companies, Type1 diabetes (Juvenile Diabetes)
Table 3: Number of Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes)
Table 4: Products under Development by Companies, Type1 diabetes (Juvenile Diabetes)
Table 5: Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes)
Table 6: Number of Products under Development for Type2 diabetes
Table 7: Number of Products under Development by Companies, Type2 diabetes
Table 8: Number of Products under Development by Universities/Institutes, Type2 diabetes
Table 9: Products under Development by Companies, Type2 diabetes
Table 10: Products under Development by Universities/Institutes, Type2 diabetes
Table 11: Number of Products under Development for Hyperinsulinemia
Table 12: Number of Products under Development by Companies, Hyperinsulinemia
Table 13: Number of Products under Development by Universities/Institutes, Hyperinsulinemia
Table 14: Products under Development by Companies, Hyperinsulinemia
Table 15: Products under Development by Universities/Institutes, Hyperinsulinemia
Table 16: Number of Products under Development for Hyperglycemia
Table 17: Number of Products under Development by Companies, Hyperglycemia
Table 18: Number of Products under Development by Universities/Institutes, Hyperglycemia
Table 19: Products under Development by Companies, Hyperglycemia
Table 20: Products under Development by Universities/Institutes, Hyperglycemia
Table 21: Number of Products by Stage and Target, Type1 diabetes (Juvenile Diabetes)
Table 22: Number of Products by Stage and Mechanism of Action, Type1 diabetes (Juvenile Diabetes)
Table 23: Number of Products by Stage and Route of Administration, Type1 diabetes (Juvenile Diabetes)
Table 24: Number of Products by Stage and Molecule Type, Type1 diabetes (Juvenile Diabetes)
Table 25: Number of Products by Stage and Target, Type2 diabetes
Table 26: Number of Products by Stage and Mechanism of Action, Type2 diabetes
Table 27: Number of Products by Stage and Route of Administration, Type2 diabetes
Table 28: Number of Products by Stage and Molecule Type, Type2 diabetes
Table 29: Number of Products by Stage and Target, Hyperinsulinemia
Table 30: Number of Products by Stage and Mechanism of Action, Hyperinsulinemia
Table 31: Number of Products by Stage and Route of Administration, Hyperinsulinemia
Table 32: Number of Products by Stage and Molecule Type, Hyperinsulinemia
Table 33: Number of Products by Stage and Target, Hyperglycemia
Table 34: Number of Products by Stage and Mechanism of Action, Hyperglycemia
Table 35: Number of Products by Stage and Route of Administration, Hyperglycemia
Table 36: Number of Products by Stage and Molecule Type, Hyperglycemia
Table 37: Type1 diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS,
Table 38: Type1 diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co KG,
Table 39: Type1 diabetes (Juvenile Diabetes) - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd,
Table 40: Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings Inc,
Table 41: Type1 diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV,
Table 42: Type1 diabetes (Juvenile Diabetes) - Pipeline by apceth Biopharma GmbH,
Table 43: Type1 diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp,
Table 44: Type1 diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB,
Table 45: Type1 diabetes (Juvenile Diabetes) - Pipeline by Arecor Ltd,
Table 46: Type1 diabetes (Juvenile Diabetes) - Pipeline by Astellas Pharma Inc,
Table 47: Type1 diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc,
Table 48: Type1 diabetes (Juvenile Diabetes) - Pipeline by Atlantic Bio Sci LLC,
Table 49: Type1 diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA,
Table 50: Type1 diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV,
Table 51: Type1 diabetes (Juvenile Diabetes) - Pipeline by Biocon Ltd,
Table 52: Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLineRx Ltd,
Table 53: Type1 diabetes (Juvenile Diabetes) - Pipeline by BioLingus AG,
Table 54: Type1 diabetes (Juvenile Diabetes) - Pipeline by Biozeus,
Table 55: Type1 diabetes (Juvenile Diabetes) - Pipeline by BirchBioMed Inc,
Table 56: Type1 diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH,
Table 57: Type1 diabetes (Juvenile Diabetes) - Pipeline by Boston Therapeutics Inc,
Table 58: Type1 diabetes (Juvenile Diabetes) - Pipeline by BTB Pharma AB,
Table 59: Type1 diabetes (Juvenile Diabetes) - Pipeline by Caladrius Biosciences Inc,
Table 60: Type1 diabetes (Juvenile Diabetes) - Pipeline by Cancer Prevention Pharmaceuticals Inc,
1.2 List of Figures
Figure 1: Number of Products under Development for Type1 diabetes (Juvenile Diabetes)
Figure 2: Number of Products under Development by Companies, Type1 diabetes (Juvenile Diabetes)
Figure 3: Number of Products under Development by Universities/Institutes, Type1 diabetes (Juvenile Diabetes)
Figure 4: Number of Products under Development for Type2 diabetes
Figure 5: Number of Products under Development by Companies, Type2 diabetes
Figure 6: Number of Products under Development by Universities/Institutes, Type2 diabetes
Figure 7: Number of Products under Development for Hyperinsulinemia
Figure 8: Number of Products under Development by Companies, Hyperinsulinemia
Figure 9: Number of Products under Development for Hyperglycemia
Figure 10: Number of Products under Development by Universities/Institutes, Hyperglycemia
Figure 11: Number of Products by Top 10 Targets, Type1 diabetes (Juvenile Diabetes)
Figure 12: Number of Products by Stage and Top 10 Targets, Type1 diabetes (Juvenile Diabetes)
Figure 13: Number of Products by Top 10 Mechanism of Actions, Type1 diabetes (Juvenile Diabetes)
Figure 14: Number of Products by Stage and Top 10 Mechanism of Actions, Type1 diabetes (Juvenile Diabetes)
Figure 15: Number of Products by Top 10 Routes of Administration, Type1 diabetes (Juvenile Diabetes)
Figure 16: Number of Products by Stage and Top 10 Routes of Administration, Type1 diabetes (Juvenile Diabetes)
Figure 17: Number of Products by Top 10 Molecule Types, Type1 diabetes (Juvenile Diabetes)
Figure 18: Number of Products by Stage and Top 10 Molecule Types, Type1 diabetes (Juvenile Diabetes)
Figure 19: Number of Products by Top 10 Targets, Type2 diabetes
Figure 20: Number of Products by Stage and Top 10 Targets, Type2 diabetes
Figure 21: Number of Products by Top 10 Mechanism of Actions, Type2 diabetes
Figure 22: Number of Products by Stage and Top 10 Mechanism of Actions, Type2 diabetes
Figure 23: Number of Products by Top 10 Routes of Administration, Type2 diabetes
Figure 24: Number of Products by Stage and Top 10 Routes of Administration, Type2 diabetes
Figure 25: Number of Products by Top 10 Molecule Types, Type2 diabetes
Figure 26: Number of Products by Stage and Top 10 Molecule Types, Type2 diabetes
Figure 27: Number of Products by Targets, Hyperinsulinemia
Figure 28: Number of Products by Stage and Targets, Hyperinsulinemia
Figure 29: Number of Products by Mechanism of Actions, Hyperinsulinemia
Figure 30: Number of Products by Stage and Mechanism of Actions, Hyperinsulinemia
Figure 31: Number of Products by Routes of Administration, Hyperinsulinemia
Figure 32: Number of Products by Stage and Routes of Administration, Hyperinsulinemia
Figure 33: Number of Products by Molecule Types, Hyperinsulinemia
Figure 34: Number of Products by Stage and Molecule Types, Hyperinsulinemia
Figure 35: Number of Products by Targets, Hyperglycemia
Figure 36: Number of Products by Stage and Targets, Hyperglycemia
Figure 37: Number of Products by Mechanism of Actions, Hyperglycemia
Figure 38: Number of Products by Stage and Mechanism of Actions, Hyperglycemia
Figure 39: Number of Products by Molecule Types, Hyperglycemia
Figure 40: Number of Products by Stage and Molecule Types, Hyperglycemia

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report